Precipio (PRPO) has entered into a distribution agreement with Cardinal Health (CAH) for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems as well as reference laboratories and physician owned laboratories.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRPO:
- Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
- Precipio reports Q4 cash burn from operations below $100,000
- Precipio trading resumes
- Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
- Precipio enters distribution agreement for IV-Cell, HemeScreen in Japan